+153.2%
MPWR vs MRNA
+27.0%
+126.3%
-51.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.2% | -3.4% | +2.2% | -1.0% |
| 7D | -1.3% | -10.1% | +8.8% | -0.7% |
| 30D | -12.8% | +126.7% | -139.6% | -22.2% |
| 3M | -21.3% | +184.1% | -205.4% | -35.3% |
| 6M | +13.7% | +143.3% | -129.5% | -3.1% |
| YTD | +33.3% | +359.9% | -326.6% | -6.2% |
| 1Y | +41.3% | +454.2% | -412.9% | -7.3% |
| All | +153.2% | +27.0% | +126.3% | +109.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling